Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising new combo aims to slow advanced colorectal cancer

NCT ID NCT07042685

First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 21 times

Summary

This study tests a new combination of chemotherapy (5FU-based) plus the targeted drug fruquintinib as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery or has spread. About 50 participants will receive the treatment in cycles, and after six months, those whose disease is stable may continue on a maintenance plan. The goal is to see how long the cancer stays under control and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Houston Methodist Neal Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.